Partner since
2020
J&J is one of the world’s largest healthcare companies and a key private sector partner of the Global Fund in several strategic areas, including leveraging core consumer insight capabilities for TB via Project InSight, driving the Ending Workplace TB (EWTB) initiative and contributing US$15 million to catalytic interventions to support Community Health Workers via the Africa Frontline First Catalytic Fund (AFF-CF).
Pledge to the Africa Frontline First Catalytic Fund (AFF-CF)
The Johnson & Johnson Foundation is among the first investors to the AFF-CF, with a contribution of US$15 million. The Global Fund intends to match this and other investments to bolster support to and domestic financing for community health workers.
More than 85% of community health workers in Africa, the majority of whom are women, are not paid for their work. Experience shows that professional community health workers - who are paid, trained, and supervised - are best equipped to provide essential health services in their communities, even amid great challenges. The AFF-CF will provide financing to accelerate and sustain the scale up of frontline community health workers, the backbone of community health services.
Africa Frontline First is a collaborative effort by the Financing Alliance for Health, Last Mile Health, the Community Health Acceleration Partnership and Community Health Impact Coalition under the championship of President Ellen Johnson Sirleaf.
Ending Workplace Tuberculosis (EWTB) founding partner
At the 2020 World Economic Forum Annual Meeting, a multi-sectoral group of partners launched a new initiative – called Ending Workplace Tuberculosis (EWTB) – aimed at engaging major businesses in the fight against tuberculosis. Initiated by the World Economic Forum, Johnson & Johnson, Royal Philips, Fullerton Health, the Confederation of Indian Industry, the Global Fund to Fight AIDS, Tuberculosis and Malaria, and the Stop TB Partnership, this initiative is leveraging the untapped potential of businesses in countries disproportionately impacted by TB to roll out awareness, detection and treatment programs, to reach millions of workers, their families and communities.
Johnson & Johnson is committing to leverage its internal resources to help suppliers across sectors – from manufacturing to research and development to logistics – conduct TB awareness raising initiatives, as well as voluntary screening and referral to care.
Behavior Change Accelerator: Project InSight
J&J collaborates with the Global Fund by contributing expertise in patient insights and experience to enhance Global Fund programming. J&J’s private sector approach to patient-centered challenges begins with in-depth research to develop deep understanding of the human experience with a disease. Through Project Insight, J&J conducted extensive research to better understand the person-centered barriers to seeking care for TB. These insights were used to map desired behaviors along a patient care journey and identify innovative new ways to accelerate TB case finding. In HIV, J&J has applied similar expertise to Global Fund supported HIV programs. Going forward, J&J is committed to collaboration with the Global Fund, ministries of health, PEPFAR and others to accelerate the design and implementation of sustainable, people-centered behavior change programs that increase the sustained uptake of essential health products and services.